BioSpace News Archive

Gritstone bio, Inc. announced that the company’s Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 46,950 shares of its common stock with an exercise price of $2.69, which is equal to the closing price of Gritstone’s common stock on December 6, 2022, the date of the grant.

Guardant Health, Inc., a leading precision oncology company, announced positive results from ECLIPSE, an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 9, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 35 new employees under Rule 5635 of the NASDAQ Listing Rules.

Ocugen, Inc. announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 —for the treatment of retinitis pigmentosa and Leber congenital amaurosis.

The Board of directors of NuGen Medical Devices Inc., a leader in needle-free drug delivery, announces the departure of Mr. Michael Wright, President and Chief Executive Officer, effective immediately.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share.

Jacobio Pharma (1167. HK) announced that the Company’s in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

G360, the parent company of both Gravity Diagnostics and Gravity+, has promoted Dr. JP Canner, Ph.D. to serve as the company’s Chief Scientific Officer.

According to the CDC, the most dangerous time of the year for drug-and-alcohol-abuse-related deaths is between December and March.

Akoya Biosciences, Inc., The Spatial Biology Company®, highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event.